A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Description of Business. We are a pharmaceutical development company that is focused on developing and ultimately commercializing innovative therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. We also have explored and expect to continue to explore acquiring or licensing other innovative pre-clinical and clinical stage therapeutics addressing unmet needs for the treatment of cancer and other diseases based on repurposing active ingredients of already approved drugs. Our current primary focus is on the development of therapies initially for basal cell carcinoma nevus syndrome (“BCCNS”), prostate and lung cancers in the United States utilizing itraconazole, a drug currently approved by the FDA to treat fungal infections, and which has an extensive history of safe and effective use in humans.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 3.0M | 3.0M | - | 0 | 0 |
| Net Income | -3.4M | -3.3M | -3.0M | 12M | -499K | -1.3M |
| EPS | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 | $0.00 |
| Free Cash Flow | 0 | -3.2M | -2.7M | 12M | -220K | -825K |
| ROIC | -90.6% | -145.6% | -57.3% | -5.5% | -437.3% | -634.9% |
| Gross Margin | - | 0.0% | 0.0% | 0.0% | - | - |
| Debt/Equity | 28.70 | 1.87 | 0.08 | 0.05 | -0.06 | -0.01 |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | -3.6M | -3.7M | -3.4M | -658K | -325K | -1.1M |
| Operating Margin | 0.0% | -121.9% | -113.5% | - | - | - |
| ROE | -99241.7% | -91.9% | -44.6% | 509.8% | - | - |
| Shares Outstanding | 173M | 167M | 151M | 172M | 377M | 377M |
Inhibitor Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Inhibitor Therapeutics, Inc. (INTI) has a 5-year average return on invested capital (ROIC) of -69.4%. This is below average and may indicate limited pricing power.
Inhibitor Therapeutics, Inc. (INTI) has a market capitalization of $14M. It is classified as a small-cap stock.
Inhibitor Therapeutics, Inc. (INTI) does not currently pay a regular dividend.
Inhibitor Therapeutics, Inc. (INTI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Inhibitor Therapeutics, Inc. (INTI) reported annual revenue of $3 million in its most recent fiscal year, based on SEC EDGAR filings.
Inhibitor Therapeutics, Inc. (INTI) has a net profit margin of -111.3%. The company is currently unprofitable.
Inhibitor Therapeutics, Inc. (INTI) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Inhibitor Therapeutics, Inc. (INTI) has a debt-to-equity ratio of 1.87. This indicates higher leverage, which may increase financial risk.
Inhibitor Therapeutics, Inc. (INTI) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
Inhibitor Therapeutics, Inc. (INTI) has a return on equity (ROE) of -91.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Inhibitor Therapeutics, Inc. (INTI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Inhibitor Therapeutics, Inc. (INTI) has a book value per share of $0.01, based on its most recent annual SEC filing.